Merck Aims to Double R&D Productivity in Oncology, Neurology and Immunology
Merck shared updates on the company’s healthcare research and development strategy, aimed at doubling R&D productivity
22-Nov-2022 -
To achieve the goal of introducing one new product or major indication every 1.5 years on average, the company will focus its expertise and capabilities and leverage synergies within the existing pipeline to deliver transformative medicines in Oncology, Neurology and Immunology, augmented by an ...
cancer
drug discovery
immunology
+3